In support of the connection between the immune system and hypertension, patients with autoimmune rheumatic diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and psoriatic arthritis/psoriasis (PsA) have prominent immune system dysfunction as well as high rates of hypertension (Al-Herz, Ensworth, Shojania, & Esdaile, 2003 Panoulas et al., 2008 Qureshi, Choi, Setty, & Curhan, 2009 Sabio et al., 2011). Increases in blood pressure are primarily attributed to perturbations in the kidney, vasculature, and CNS, but both clinical and experimental evidence implicate the immune system in the pathogenesis of essential hypertension (Rodriguez-Iturbe et al., 2014). The burden of hypertension globally suggests that there is a continued need to understand the underlying mechanisms that contribute to its development. Despite improvements in treatment and the development of many classes of antihypertensive drugs over the past century, only about one quarter of patients who receive medication achieve blood pressure control (Mills et al., 2016). It is estimated that over 1 billion people worldwide have hypertension with disease complications contributing to 10 million largely preventable deaths each year (Collaborators, 2016). To view the other articles in this section visit This article is part of a themed section on Immune Targets in Hypertension.
This review examines the prevalent hypertension, the immune mediators that contribute to the prevalent hypertension and their impact on renal function and how the risk of hypertension is potentially influenced by common hormonal changes that are associated with autoimmune rheumatic diseases. Therefore, examining the link between autoimmunity and hypertension can be informative for understanding primary hypertension. Many of the proposed immunological mechanisms leading to primary hypertension are paralleled in autoimmune rheumatic disorders.
There is now a large body of evidence showing that the immune system is a key mediator in both human primary hypertension and experimental models. Patients with autoimmune rheumatic diseases including rheumatoid arthritis and systemic lupus erythematosus have an increased prevalence of hypertension.
0 kommentar(er)
